Related Experiment Videos
New perspectives in the treatment of prostate cancer
1Department of Urology, University Hospital Nijmegen, The Netherlands.
Abstract:
Current androgen ablation therapies for advanced prostate cancer are not curative. Several recently identified critical biochemical pathways, including the E-cadherin/catenin complex, programmed cell death, telomerase activity, and receptor kinases, may represent targets for new therapeutic approaches. Different forms of gene therapy are also being investigated. Drug development is at the pre-clinical stage, but phase I and II clinical trials are planned, and may lead to a wider choice of therapeutic options for prostate cancer in the not too distant future.
Insights
New therapeutic strategies are being developed for advanced prostate cancer, targeting key biochemical pathways and gene therapy. These approaches are in early development but may offer more treatment options soon.
Area of Science:
- Oncology
- Biochemistry
- Genetics
Background:
- Current androgen ablation therapies for advanced prostate cancer lack curative potential.
- Novel therapeutic targets are emerging from recent biochemical pathway discoveries.
Purpose of the Study:
- To explore new therapeutic targets for advanced prostate cancer.
- To investigate the potential of novel biochemical pathways and gene therapy.
Main Methods:
- Identification of critical biochemical pathways: E-cadherin/catenin complex, programmed cell death, telomerase activity, and receptor kinases.
- Investigation of different forms of gene therapy.
Main Results:
- Several critical biochemical pathways have been identified as potential therapeutic targets.
- Gene therapy approaches are under investigation for prostate cancer treatment.
Conclusions:
- Emerging therapeutic targets and gene therapy offer promise for advanced prostate cancer.
- Drug development is in the pre-clinical stage with clinical trials planned, potentially expanding future treatment options.